2022 American Transplant Congress
Cytomegalovirus Prevention in Kidney and Pancreas Transplant Recipients: A Successful Pharmacist-Led Multidisciplinary Approach
University of Virginia Health, Charlottesville, VA
*Purpose: In response to high cytomegalovirus (CMV) infection and increasing ganciclovir (GCV)-resistance rate, a pharmacist-led multidisciplinary task force was created to manage CMV prophylaxis (ppx).…2022 American Transplant Congress
Post-Kidney Transplant Valacyclovir versus Valganciclovir for CMV Prophylaxis: A Randomized Controlled Trial
*Purpose: Valganciclovir (valG) is an effective CMV prophylactic agent post-kidney transplant (KTx) with significant side effects. Valacyclovir (valA) may be effective for CMV prophylaxis with…2022 American Transplant Congress
Burden of Leukopenia/Neutropenia Among Adult Kidney Transplant Recipients: A Systematic Literature Review of Observational Studies
*Purpose: Leukopenia/neutropenia (L/N) may affect key treatment decisions which could result in poor clinical and economic outcomes among kidney transplant recipients (KTRs). The burden of…2021 American Transplant Congress
Clinical Consequences in Patients Experiencing Leukopenia and Neutropenia After Solid Organ Transplant
*Purpose: The incidence of leukopenia and neutropenia in solid organ transplant (SOT) recipients can be influenced by medications required after transplant for immunosuppression and infection…2021 American Transplant Congress
Delayed Valganciclovir Initiation and the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients
Keck Medical Center of USC, Los Angeles, CA
*Purpose: Opportunistic infections remain a significant burden after liver transplantation, particularly cytomegalovirus (CMV) infection. With the use of valganciclovir (VGCV), the incidence of CMV infection…2021 American Transplant Congress
Outcomes Among CMV Mismatched and Highly Sensitized Kidney Transplant Recipients Who Develop Leukopenia or Neutropenia
*Purpose: Kidney transplant recipients (KTRs) who receive antiproliferative agents for immunosuppression and valganciclovir for CMV prophylaxis are at high risk of developing leukopenia and neutropenia.…2021 American Transplant Congress
Outcomes of Granulocyte-Colony Stimulating Factor Use in Pediatric Renal Transplant Recipients: A Pediatric Nephrology Research Consortium Study
*Purpose: Neutropenia is common after pediatric kidney transplant and is associated with an increased risk of bacterial infection, allograft loss, and death. Granulocyte colony-stimulating factor…2021 American Transplant Congress
Systematic Evaluation of Immunosuppressant Drug Tolerability in Lung Transplant Recipients with Short Telomere Syndrome
*Purpose: Lung transplant recipients with short telomere syndrome are at high risk of hematologic complications. Consequently, patients with short telomere syndrome may require more frequent…2021 American Transplant Congress
Use of Granulocyte Colony Stimulating Factor After Lung Transplantation is Not Associated with Increased Likelihood of Acute Cellular Rejection
*Purpose: The cause of neutropenia in lung transplant recipients is multifactorial, including medications, viral infections, and antecedent disease. Granulocyte colony-stimulating factor (G-CSF) is commonly used…2021 American Transplant Congress
Evaluation of a Weight-Based Mycophenolate Mofetil Dosing Protocol for Kidney Transplant Maintenance Immunosuppression
*Purpose: To evaluate the safety and efficacy of a weight-based mycophenolate mofetil (MMF) dosing protocol in adult kidney transplant recipients (KTR).*Methods: This single-center retrospective study…
- 1
- 2
- 3
- 4
- Next Page »